• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Pregnancy and Postpartum Course
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Pregnancy and Postpartum Course
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Do Antipsychotics Increase Breast Cancer Risk?
Research Update

Do Antipsychotics Increase Breast Cancer Risk?

July 1, 2025
Alaina Burns, MD
From The Carlat Hospital Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Alaina Burns, MD. Dr. Burns has no financial relationships with companies related to this material. 

Getting your Trinity Audio player ready...

Review of: Solmi M et al, Schizophr Bull 2024;50(6):1471–1481 

Study Type: Retrospective case-control study

People with severe mental illness face a shortened life expectancy for various reasons, including higher rates of cardiovascular disease and limited access to medical care. Could the long-term use of certain antipsychotic medications also increase the risk of breast cancer? 

The efficacy of antipsychotics has been linked to dopamine blockade in the striatum. However, simultaneous blockade of dopamine receptors in other brain pathways can lead to hyperprolactinemia, which has been associated with an increased risk of breast cancer in animal studies (Johnston AN et al, Breast Cancer Res 2018;20(1):42). This study explores the potential link between antipsychotic use and breast cancer risk among women with severe mental illness.

Using Swedish national health registers, researchers identified women with schizophrenia, schizoaffective disorder, other nonaffective psychotic disorders, or bipolar disorder (n=132,061). Among these, women diagnosed with breast cancer between 2010 and 2021 (n=1,642) were matched with controls (n=8,173) by age, primary psychiatric diagnosis, and disease duration.

Antipsychotic medications were categorized as prolactin-sparing (clozapine, quetiapine, aripiprazole, brexpiprazole, and cariprazine) or prolactin-raising (all others). Duration of use was classified as <1 year, 1–4 years, or ≥5 years. The analysis considered cumulative doses and adjusted for confounding factors such as medical comorbidities and use of other medications.

Women exposed to prolactin-raising antipsychotics for 1–4 years had a 20% increased risk of developing breast cancer, and those with ≥5 years of exposure had 47% increased risk. Women taking prolactin-sparing antipsychotics did not show an increase in breast cancer risk regardless of the duration of use. The study also found consistent results across cancer types, with prolonged exposure to prolactin-raising antipsychotics associated with an increased risk of both ductal and lobular adenocarcinoma.

Carlat Take

This study strengthens the evidence linking long-term use of prolactin-raising antipsychotics with an increased risk of breast cancer. While it does not establish causality, the dose-response relationship—showing higher risk with longer duration of exposure—adds indirect evidence supporting a possible causal link. Unmeasured confounders, such as obesity and health care utilization patterns, may have inflated the observed risks, which should temper our confidence in the findings.

Nonetheless, these findings highlight the importance of closely monitoring prolactin levels in female patients who are prescribed prolactin-raising antipsychotics, even if the patients are asymptomatic. Be sure to encourage regular breast cancer screenings (eg, mammograms) to detect potential issues early. For women who have additional breast cancer risk factors, such as a family history of breast cancer, obesity, or smoking, consider prescribing prolactin-sparing antipsychotics (eg, clozapine, quetiapine, aripiprazole, brexpiprazole, and cariprazine) as an alternative. 

Hospital Psychiatry
KEYWORDS antipsychotics breast cancer medication safety prolactin side effects women’s mental health
    Alaina Burns, MD

    How Soon Is Soon Enough When Predicting Antipsychotic Nonresponse?

    More from this author
    www.thecarlatreport.com
    Issue Date: July 1, 2025
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Burnout & Clinician Well-Being, CHPR, July/August/September 2025
    Making the Case: How to Reduce Insurance Denials in Psychiatric Care
    Breaking the Stigma: Helping Physicians Seek and Sustain Recovery
    De-Escalation and Reducing Violence in Psychiatric Care
    Burnout: Causes, Risks, and Remedies  
    Do Antipsychotics Increase Breast Cancer Risk?
    CME Post-Test, Burnout & Clinician Well-Being, CHPR, July/August/September 2025
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2637648401.jpg
      General Psychiatry

      Psychopharm Secrets: Coming Off Meds

      There’s a hidden placebo response to watch for when patients stop meds on their own.
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.